Bevacizumab biosimilar - Cipla BioTec

Drug Profile

Bevacizumab biosimilar - Cipla BioTec

Alternative Names: CBT-124

Latest Information Update: 30 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cipla BioTec
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 22 Aug 2016 Cipla BioTec plans a phase III trial for Non-small cell lung cancer (Late-stage disease, Inoperable or Unresectable, Recurrent, Metastatic disease, First-line therapy, Combination therapy) Bulgaria, India, Hungary, South Africa and Ukraine (IV) (NCT02879097)
  • 01 Jun 2016 Phase-I clinical trials in Cancer (In volunteers) in New Zealand (IV)
  • 29 Apr 2016 Preclinical trials in Cancer in Australia (IV) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top